HM
ACRV icon

HealthCor Management’s Acrivon Therapeutics ACRV Stock Holding History

HealthCor Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.27M Buy
+284,201
New +$3.61M 3% 4

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HealthCor Management's ACRV Position: Q4 2022 in Review

HealthCor Management opened a new position in Acrivon Therapeutics (ACRV) in Q4 2022: 284,201 shares worth $3.27M. The stake represents 3% of the portfolio and ranks #4 among its holdings.

18 funds tracked by Wall St. Rank hold ACRV as of Q4 2022.

  • HealthCor Management held 284,201 shares of Acrivon Therapeutics worth $3.27M as of Q4 2022.
  • Acrivon Therapeutics was a new HealthCor Management position in Q4 2022.
  • Acrivon Therapeutics made up 3% of HealthCor Management's portfolio in Q4 2022, its #4 holding.
  • 18 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.